0001193125-14-271013.txt : 20140717 0001193125-14-271013.hdr.sgml : 20140717 20140717071500 ACCESSION NUMBER: 0001193125-14-271013 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 4 CONFORMED PERIOD OF REPORT: 20140711 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20140717 DATE AS OF CHANGE: 20140717 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BAXTER INTERNATIONAL INC CENTRAL INDEX KEY: 0000010456 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 360781620 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-04448 FILM NUMBER: 14979246 BUSINESS ADDRESS: STREET 1: ONE BAXTER PKWY STREET 2: DF2-1W CITY: DEERFIELD STATE: IL ZIP: 60015 BUSINESS PHONE: 8479482000 MAIL ADDRESS: STREET 1: ONE BAXTER PARKWAY STREET 2: DF2-1W CITY: DEERFIELD STATE: IL ZIP: 60015 FORMER COMPANY: FORMER CONFORMED NAME: BAXTER TRAVENOL LABORATORIES INC DATE OF NAME CHANGE: 19880522 FORMER COMPANY: FORMER CONFORMED NAME: BAXTER LABORATORIES INC DATE OF NAME CHANGE: 19760608 8-K 1 d758846d8k.htm FORM 8-K FORM 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) July 11, 2014

Baxter International Inc.

 

(Exact name of registrant as specified in its charter)

Delaware

 

(State or other jurisdiction of incorporation)

 

1-4448   36-0781620
(Commission File Number)   (IRS Employer Identification No.)

 

One Baxter Parkway, Deerfield, Illinois   60015
(Address of principal executive offices)   (Zip Code)

(224) 948-2000

 

(Registrant’s telephone number, including area code)

 

                      

 

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Item 1.01. Entry into a Material Definitive Agreement.

On July 11, 2014, Baxter International Inc. (Company) and the applicable counterparties thereto entered into Amendment No. 1 (Amendment No. 1) to the Company’s four-year revolving credit agreement (Four-Year Credit Agreement), dated as of June 17, 2011, among the Company, as Borrower, JPMorgan Chase Bank, N.A., as Administrative Agent, Bank of America, N.A. and Citibank, N.A., as Syndication Agents, J.P. Morgan Securities LLC, Merrill Lynch, Pierce, Fenner & Smith Incorporated and Citigroup Global Markets Inc. as Co-Lead Arrangers and Joint Bookrunners, and the lenders party thereto. Amendment No. 1 amends certain sections of the Four-Year Credit Agreement, including extending the date included in the definition of Termination Date from June 17, 2015 to December 31, 2015.

This summary of Amendment No. 1 is qualified in its entirety by reference to the complete text of such agreement, a copy of which is attached to this report as Exhibit 10.1 and incorporated herein by reference.

Item 2.02. Results of Operations and Financial Condition.

On July 17, 2014, the Company issued an earnings press release for the quarterly period ended June 30, 2014. The press release, including attachments, is furnished as Exhibit 99.1 to this report.

The press release furnished as Exhibit 99.1 contains financial measures that are not calculated in accordance with generally accepted accounting principles (GAAP). The non-GAAP financial measures include adjusted net income, adjusted earnings per diluted share and adjusted pre-tax income, each excluding special items. Special items are excluded because they are highly variable, difficult to predict, and of a size that may substantially impact the Company’s reported operations for a period. Non-GAAP financial measures may provide a more complete understanding of the Company’s operations and can facilitate a fuller analysis of the Company’s results of operations, particularly in evaluating performance from one period to another. Upfront and milestone payments related to collaborative arrangements that have been expensed as research and development (R&D) are uncertain and often result in a different payment and expense recognition pattern than internal R&D activities and therefore are typically excluded as special items. In addition, beginning with the first quarter of 2014, the Company has reported adjusted earnings measures excluding intangible asset amortization expense. To facilitate comparisons to the prior period we have provided adjusted net income, adjusted earnings per share and adjusted pre-tax income excluding intangible asset amortization expense for both the three- and six-month periods ending June 30, 2013. Intangible asset amortization is excluded as a special item to facilitate an evaluation of current and past operating performance, particularly in terms of cash returns, and is similar to how management internally assesses performance.

Management believes that non-GAAP earnings measures, when used in conjunction with the results presented in accordance with GAAP and the reconciliations to corresponding GAAP financial measures, may enhance an investor’s overall understanding of the Company’s past financial performance and prospects for the future. Accordingly, management uses these non-GAAP measures internally in financial planning, to monitor business unit performance, and in some cases for purposes of determining incentive compensation.


The press release also includes the non-GAAP financial measure of net debt, which represents the difference between total debt (defined as short-term debt, current maturities of long-term debt and lease obligations, and long-term debt and lease obligations) and cash and equivalents. Management uses net debt for internal planning purposes and to monitor compliance with the Company’s primary credit facilities as net debt corresponds with certain financial covenants contained therein.

The Company strongly encourages investors to review its consolidated financial statements and publicly filed reports in their entirety and cautions investors that the non-GAAP measures used by the Company may differ from similar measures used by other companies, even when similar terms are used to identify such measures.

Item 9.01. Financial Statements and Exhibits.

 

  (d) Exhibits.

 

  10.1 Amendment No. 1, dated July 11, 2014, to the Four-Year Credit Agreement dated June 17, 2011.

 

  99.1 Press Release dated July 17, 2014.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

BAXTER INTERNATIONAL INC.
By:   /S/ DAVID P. SCHARF
  David P. Scharf
  Corporate Vice President,
  General Counsel and
  Corporate Secretary

Date: July 17, 2014


Exhibit Index

 

Exhibit No.

  

Description

10.1    Amendment No. 1, dated July 11, 2014, to the Four-Year Credit Agreement dated June 17, 2011.
99.1    Press Release dated July 17, 2014.
EX-10.1 2 d758846dex101.htm EX-10.1 EX-10.1

Exhibit 10.1

AMENDMENT NO. 1 TO CREDIT AGREEMENT

This AMENDMENT NO. 1 TO CREDIT AGREEMENT (this “Amendment”) is made as of July 11, 2014 among Baxter International Inc., a Delaware corporation (the “Borrower”), JPMorgan Chase Bank, N.A., as administrative agent under the hereinafter defined Credit Agreement (the “Administrative Agent”), and the other financial institutions signatory hereto.

R E C I T A L S:

A. The Borrower, the Administrative Agent and certain financial institutions are parties to a $1,500,000,000 Credit Agreement dated as of June 17, 2011 (the “Credit Agreement”).

B. The Borrower, the Administrative Agent and the undersigned Banks wish to amend the Credit Agreement on the terms and conditions set forth below.

Now, therefore, in consideration of the mutual execution hereof and other good and valuable consideration, the parties hereto agree as follows:

1. Definitions. Unless otherwise specified herein, all capitalized terms used herein shall have the meanings specified in the Credit Agreement.

2. Amendments to Credit Agreement. Upon the First Amendment Effective Time (as defined below), the Credit Agreement shall be amended as follows:

(a) The definition of “Eurocurrency Rate” in Section 1.01 of the Credit Agreement is amended in its entirety to read as follows:

Eurocurrency Rate” means, with respect to any Eurocurrency Advance in an Agreed Currency (other than Euro) for the relevant Interest Period, the London interbank offered rate as administered by Ice Benchmark Administration (“ICE”) (or any other Person that takes over the administration of such rate) for the applicable Agreed Currency for a period equal in length to such Interest Period as displayed on pages LIBOR01 or LIBOR02 of the Reuters screen that displays such rate (or, in the event such rate does not appear on a Reuters page or screen, on any successor or substitute page on such screen that displays such rate, or on the appropriate page of such other information service that publishes such rate from time to time as selected by the Administrative Agent in its reasonable discretion); provided, that, if no such rate is available to the Administrative Agent, the applicable Eurocurrency Rate for the relevant Interest Period shall instead be the rate determined by reference to such other publicly available service for displaying interest rates for deposits in the applicable Agreed Currency in the London interbank market as may be selected by the Administrative Agent or, in the absence of such availability, by reference to the average of the rates at which deposits in the applicable Agreed Currency of $5,000,000 and for a maturity comparable to such Interest Period are offered in immediately available funds in the London interbank market at approximately 11:00 a.m., London time, two Business Days prior to the commencement of such Interest Period by the principal London office of the Administrative Agent and by one or more Banks which are selected by the Administrative Agent and which agree to provide such information to the Administrative Agent; and provided further that if the “Eurocurrency Rate” as determined pursuant to the foregoing provisions of this


definition shall be less than zero, such rate shall be deemed to be zero for the purposes of this Agreement.

(b) The definition of “EURIBOR” in Section 1.01 of the Credit Agreement is amended in its entirety to read as follows:

EURIBOR” means, with respect to any EURIBOR Advance for the relevant Interest Period, the interest rate per annum equal to the rate determined by the Administrative Agent to be the rate at which deposits in Euro appear on the Reuters Screen EURIBOR01 as of 11:00 a.m., Brussels time, on the date that is two (2) TARGET Settlement Days (or, if such date is not a EURIBOR Business Day, the first day preceding such date that is a EURIBOR Business Day) preceding the first day of such Interest Period, and having a maturity equal to such Interest Period; provided, that if such rate does not appear on the Reuters Screen EURIBOR01, then EURIBOR shall be an interest rate per annum equal to the arithmetic mean determined by the Administrative Agent (rounded to the nearest .01%) of the rates per annum at which deposits in Euro are offered by the London branches of JPMorgan Chase Bank, National Association, Bank of America, N.A. and Citibank, N.A. at approximately 11:00 a.m., Brussels time, on the day that is two (2) TARGET Settlement Days (or, if such date is not a EURIBOR Business Day, the first day preceding such date that is a EURIBOR Business Day) preceding the first day of such Interest Period to other leading banks in the euro-zone interbank market at which deposits in Euro are offered, and having a maturity equal to such Interest Period. The Administrative Agent will deliver a copy of such Reuters Screen or its calculation of EURIBOR, as applicable, to the Borrower within one (1) EURIBOR Business Day of the beginning of the relevant Interest Period; provided that the failure of the Administrative Agent to provide such copy of the Reuters Screen or such calculation of EURIBOR shall in no way limit or modify the obligations of the Borrower under this Agreement; and provided further that if “EURIBOR” as determined pursuant to the foregoing provisions of this definition shall be less than zero, such rate shall be deemed to be zero for the purposes of this Agreement.

(c) The definition of “Termination Date” in Section 1.01 of the Credit Agreement is amended in its entirety to read as follows:

Termination Date” means, the earlier of (i) December 31, 2015 and (ii) the date on which the Commitments shall have been reduced to zero or terminated in whole pursuant to the terms hereof.

(d) The following definitions shall be added to Section 1.01 of the Credit Agreement in alphabetical order:

Anti-Corruption Laws” means all laws, rules, and regulations of any jurisdiction applicable to the Borrower or its Subsidiaries from time to time concerning or relating to bribery or corruption.

Sanctions” means economic or financial sanctions or trade embargoes imposed, administered or enforced from time to time by (a) the U.S. government, including those administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury or

 

2


the U.S. Department of State or (b) the United Nations Security Council, the European Union or Her Majesty’s Treasury of the United Kingdom.

Sanctioned Country” means, at any time, a country or territory which is the subject or target of any Sanctions and currently is comprised of Cuba, Iran, North Korea, Sudan and Syria.

Sanctioned Person” means, at any time, (a) any Person listed in any Sanctions-related list of designated Persons maintained by the Office of Foreign Assets Control of the U.S. Department of the Treasury, the U.S. Department of State or by the United Nations Security Council, the European Union or any European Union member state, (b) any Person operating, organized or resident in a Sanctioned Country or (c) any Person controlled or more than 50% owned by any such Person.

(e) Section 7.01(f) of the Credit Agreement is amended in its entirety to read as follows:

Financial Statements; No Material Adverse Change. The Consolidated balance sheet at December 31, 2013, and the related Consolidated statements of income, cash flows and shareholder’s equity and comprehensive income for the period then ended of the Borrower and its Consolidated Subsidiaries present fairly in all material respects the financial condition of the Borrower and its Consolidated Subsidiaries at December 31, 2013, and the results of the operations and cash flows of the Borrower and its Consolidated Subsidiaries for the year then ended, in conformity with generally accepted accounting principles applied on a basis consistent with that of the preceding year except as discussed in Note 1 to the Consolidated financial statements. Since December 31, 2013, except as disclosed in filings with the SEC prior to the date of this Agreement, there has been no material adverse change in such financial condition or operations.

(f) A new Section 7.01(j) is added to the Credit Agreement reading as follows:

Anti-Corruption Laws and Sanctions. The Borrower has implemented and maintains in effect policies and procedures designed to ensure compliance by the Borrower, its Subsidiaries and their respective directors, officers, employees and agents with Anti-Corruption Laws and applicable Sanctions, and the Borrower, its Subsidiaries and their respective officers and employees and to the knowledge of the Borrower its directors and agents, are in compliance with Anti-Corruption Laws and applicable Sanctions in all material respects. None of (a) the Borrower, any Subsidiary or, to the knowledge of the Borrower or such Subsidiary, any of their respective directors, officers or employees, or (b) to the knowledge of the Borrower, any agent of the Borrower or any Subsidiary that will act in any capacity in connection with or benefit from the credit facility established hereby, is a Sanctioned Person, except to the extent the Borrower or such Subsidiary is licensed by the appropriate Sanctions-administering authority to engage in the applicable transaction with such Sanctioned Person or is otherwise permitted to do so by U.S. law. No Borrowing or Letter of Credit, use of proceeds or other transaction contemplated by the Credit Agreement will violate Anti-Corruption Laws or applicable Sanctions.

 

3


(g) Section 8.01(g) of the Credit Agreement is amended by adding the following sentence at the conclusion thereof:

The Borrower will not request any Advance or Letter of Credit, and the Borrower shall not use, and shall procure that its Subsidiaries and its or their respective directors, officers, employees and agents shall not use, the proceeds of any Advance or Letter of Credit (A) in furtherance of an offer, payment, promise to pay, or authorization of the payment or giving of money, or anything else of value, to any Person in violation of any Anti-Corruption Laws, (B) for the purpose of funding, financing or facilitating any activities, business or transactions of or with any Sanctioned Person, or in any Sanctioned Country, except to the extent licensed by the appropriate Sanctions-administering authority to engage in the applicable transaction with such Sanctioned Person or, as applicable, in such Sanctioned Country or otherwise permitted by U.S. law, or (C) in any manner that would result in the violation of any Sanctions applicable to any party hereto.

(h) A new Section 8.01(h) is added to the Credit Agreement reading as follows:

Anti-Corruption Policies, Etc. The Borrower will maintain in effect and enforce policies and procedures designed to ensure compliance by the Borrower, its Subsidiaries and their respective directors, officers, employees and agents with Anti-Corruption Laws and applicable Sanctions.

(i) Section 9.01(d) of the Credit Agreement is amended in its entirety to read as follows:

The Borrower shall (i) fail to perform or observe, or shall breach, any other term, covenant or agreement contained in this Agreement on its part to be performed or observed (other than those failures or breaches referred to in subsections (a), (b), (c), (d)(ii) or (d)(iii) of this Section 9.01) and any such failure or breach shall remain unremedied for thirty (30) days after written notice thereof has been given to the Borrower by the Administrative Agent at the request of any Bank; (ii) fail to perform or observe Section 8.02(c) or the final sentence of Section 8.01(g); or (iii) fail to perform or observe Section 8.01(f)(v) and such failure shall remain unremedied for fifteen (15) days after the occurrence thereof;

3. Representations and Warranties of the Borrower. The Borrower represents and warrants that:

(a) The execution, delivery and performance by the Borrower of this Amendment have been duly authorized by all necessary corporate action and that this Amendment is a legal, valid and binding obligation of the Borrower enforceable against the Borrower in accordance with its terms, except as the enforcement thereof may be subject to the effect of any applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors’ rights generally;

(b) Each of the representations and warranties contained in the Credit Agreement (as amended hereby) is true and correct in all material respects (provided that each representation and warranty which is already qualified by materiality is true and

 

4


correct in all respects) on and as of the date hereof as if made on the date hereof (except any such representation or warranty that expressly relates to or is made expressly as of a specific earlier date, in which case such representation or warranty is true and correct in all material respects (provided that each representation and warranty which is already qualified by materiality is true and correct in all respects) with respect to or as of such specific earlier date); and

(c) No Event of Default or Unmatured Event of Default has occurred and is continuing.

4. Effective Time. This Amendment shall become effective on the date (the “First Amendment Effective Time”) upon which all of the following conditions have been satisfied:

(a) the execution and delivery hereof by the Borrower, the Administrative Agent and each of the Banks; and

(b) the Borrower shall have paid to J.P. Morgan Securities LLC (i) the separately agreed fees relating hereto and (ii) all reasonable expenses reimbursable by the Borrower pursuant hereto or to the Credit Agreement for which invoices have been presented by the Administrative Agent on or before the First Amendment Effective Time.

5. Miscellaneous.

(a) Except as specifically amended hereby, the Credit Agreement, the Notes and the other agreements, instruments and documents executed in connection therewith (collectively, the “Loan Documents”) shall remain in full force and effect and are hereby ratified and confirmed.

(b) The execution, delivery and effectiveness of this Amendment shall not operate as a waiver of any right, power or remedy of the Administrative Agent or any Bank under the Credit Agreement or any other Loan Document, or constitute a waiver of any provision of the Credit Agreement or any other Loan Document. Upon the effectiveness of this Amendment, each reference in the Credit Agreement to “this Agreement”, “hereunder”, “hereof”, “herein” or words of similar import shall mean and be a reference to the Credit Agreement as amended hereby.

(c) Section headings in this Amendment are included herein for convenience of reference only and shall not constitute a part of this Amendment for any other purposes.

(d) This Amendment may be executed in any number of counterparts, each of which when so executed shall be deemed an original but all such counterparts shall constitute one and the same instrument. Delivery of an executed signature page of this Amendment by facsimile transmission or other electronic transmission shall be effective as delivery of a manually executed counterpart hereof.

6. Costs and Expenses. The Borrower hereby affirms its obligation under Section 11.04 of the Credit Agreement to reimburse the Administrative Agent for all reasonable and

 

5


documented out-of-pocket expenses incurred by the Administrative Agent in connection with the preparation, negotiation, execution and delivery of this Amendment, including but not limited to the reasonable and documented fees, charges and disbursements of attorneys for the Administrative Agent with respect thereto.

7. Governing Law. This Amendment shall be governed by, and construed in accordance with, the laws of the State of New York.

[signature pages follow]

 

6


IN WITNESS WHEREOF, the parties have executed this Amendment as of the date and year first above written.

 

BAXTER INTERNATIONAL INC.
By:  

/s/ Robert J. Hombach

Name:   Robert J. Hombach
Title:   Corporate Vice President and
  Chief Financial Officer

Signature Page to Baxter International

Amendment No. 1 to Credit Agreement


JPMORGAN CHASE BANK, N.A.,
as Administrative Agent and as a Bank
By:  

/s/ Olivier Lopez

Name:   Olivier Lopez
Title:   Associate

Signature Page to Baxter International

Amendment No. 1 to Credit Agreement


BANK OF AMERICA, N.A.
By:  

/s/ Joseph Corah

Name:   Joseph Corah
Title:   Director

Signature Page to Baxter International

Amendment No. 1 to Credit Agreement


CITIBANK, N.A.
By:  

/s/ Laura Fogarty

Name:   Laura Fogarty
Title:   Vice President

Signature Page to Baxter International

Amendment No. 1 to Credit Agreement


DEUTSCHE BANK AG NEW YORK BRANCH,
as a Lender
By:  

/s/ Ming K. Chu

Name:   Ming K. Chu
Title:   Vice President
By:  

/s/ Virginia Cosenza

Name:   Virginia Cosenza
Title:   Vice President

Signature Page to Baxter International

Amendment No. 1 to Credit Agreement


GOLDMAN SACHS BANK USA
By:  

/s/ Mark Walton

Name:   Mark Walton
Title:   Authorized Signature

Signature Page to Baxter International

Amendment No. 1 to Credit Agreement


UBS AG, STAMFORD BRANCH
By:  

/s/ Lana Gifas

Name:   Lana Gifas
Title:   Director
By:  

/s/ Jennifer Anderson

Name:   Jennifer Anderson
Title:   Associate Director

Signature Page to Baxter International

Amendment No. 1 to Credit Agreement


CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH
By:  

/s/ Christopher Day

Name:   Christopher Day
Title:   Authorized Signatory
By:  

/s/ Sally Reyes

Name:   Sally Reyes
Title:   Authorized Signatory

Signature Page to Baxter International

Amendment No. 1 to Credit Agreement


THE ROYAL BANK OF SCOTLAND PLC
By:  

/s/ William McGinty

Name:   William McGinty
Title:   Director

Signature Page to Baxter International

Amendment No. 1 to Credit Agreement


THE BANK OF TOKOYO-MITSUBISHI UFJ, LTD.
By:  

/s/ Jaime Sussman

Name:   Jaime Sussman
Title:   Authorized Signatory

Signature Page to Baxter International

Amendment No. 1 to Credit Agreement


BARCLAYS BANK PLC
By:  

/s/ Paras Patel

Name:   Paras Patel
Title:   Vice President

Signature Page to Baxter International

Amendment No. 1 to Credit Agreement


HSBC BANK USA, N.A.
By:  

/s/ Andrew Bicker

Name:   Andrew Bicker
Title:   Senior Vice President

Signature Page to Baxter International

Amendment No. 1 to Credit Agreement


MIZUHO BANK (USA) f/k/a/ MIZUHO CORPORATE BANK (USA)
By:  

/s/ Bertram H. Tang

Name:   Bertram H. Tang
Title:   Senior Vice President

Signature Page to Baxter International

Amendment No. 1 to Credit Agreement


BANK OF CHINA, NEW YORK BRANCH
By:  

/s/ Haifeng Xu

Name:   Haifeng Xu
Title:   Executive Vice President

Signature Page to Baxter International

Amendment No. 1 to Credit Agreement


THE BANK OF NEW YORK MELLON
By:  

/s/ Clifford A. Mull

Name:   Clifford A. Mull
Title:   First Vice President

Signature Page to Baxter International

Amendment No. 1 to Credit Agreement


TORONTO DOMINION (TEXAS) LLC
By:  

/s/ Marie Fernandes

Name:   Marie Fernandes
Title:   Authorized Signatory

Signature Page to Baxter International

Amendment No. 1 to Credit Agreement


STATE STREET BANK & TRUST COMPANY
By:  

/s/ Andrei Bourdine

Name:   Andrei Bourdine
Title:   Vice President

Signature Page to Baxter International

Amendment No. 1 to Credit Agreement

EX-99.1 3 d758846dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

FOR IMMEDIATE RELEASE

Media Contact:

Deborah Spak, (224) 948-2349

Investor Contacts:

Mary Kay Ladone, (224) 948-3371

Clare Trachtman, (224) 948-3085

BAXTER EXCEEDS EXPECTATIONS IN SECOND QUARTER WITH STRONG

GROWTH ACROSS GLOBAL FRANCHISES

Company Confirms Full-Year 2014 Outlook, Narrows EPS Range

DEERFIELD, Ill., July 17, 2014 — Baxter International Inc. (NYSE:BAX) today reported strong growth across its global franchises in the second quarter, generating sales and earnings that exceeded the company’s previously issued guidance. The company also confirmed its financial outlook for 2014, narrowing the guidance range for adjusted earnings per diluted share to $5.10 to $5.20.

Baxter posted net income of $520 million and earnings per diluted share of $0.95 in the second quarter, compared to net income of $590 million and earnings per diluted share of $1.07 in the same period last year. Second quarter 2014 results include net after-tax special items totaling $172 million (or $0.31 per diluted share) primarily for intangible amortization and costs associated with contingent revenue and product development milestone payments, remediation efforts related to the in-progress SPECTRUM Infusion Pump recall, integration of the company’s acquisition of Gambro AB, and Baxter’s planned separation into two independent healthcare companies. These charges were partially offset by the reversal of certain business optimization and litigation reserves. Second

 

- more -


BAXTER REPORTS 2nd QUARTER FINANCIAL RESULTS — Page  2

 

quarter 2013 results included after-tax special items totaling $69 million (or $0.13 per diluted share).

On an adjusted basis, excluding special items in both periods, Baxter’s second quarter net income of $692 million increased 5 percent from $659 million reported in 2013. Adjusted earnings per diluted share of $1.26 also increased 5 percent from $1.20 per diluted share last year, exceeding the company’s previously issued earnings guidance of $1.18 to $1.22 per diluted share.

Worldwide sales totaled $4.3 billion, which advanced 16 percent from $3.7 billion reported in the same period last year. Sales within the United States grew 12 percent to $1.7 billion, and international sales of $2.5 billion increased 19 percent (foreign currency had no impact on sales growth). Excluding the contribution of Gambro revenues in the quarter totaling $408 million, Baxter’s worldwide sales rose 5 percent.

BioScience revenues advanced 7 percent to $1.8 billion compared to the prior-year period. Excluding the impact of foreign currency, BioScience sales rose 6 percent, with solid growth reported across all the global franchises. Performance was led by double-digit growth of ADVATE [Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method] and albumin, as well as increased global demand for GAMMAGARD LIQUID [Immune Globulin Intravenous (Human)], biosurgery products and select vaccines.

Medical Products sales of $2.5 billion grew 24 percent from the prior-year period, and excluding revenues associated with the Gambro acquisition, Medical Products sales increased 4 percent (foreign currency had no impact on sales growth). This performance was driven primarily by strong sales of injectable

 

- more -


BAXTER REPORTS 2nd QUARTER FINANCIAL RESULTS — Page  3

 

drugs, anesthetics and nutritional therapies, as well as gains in peritoneal dialysis patients, particularly in the U.S. and emerging markets.

“We are driving solid performance across our entire business portfolio, and advancing care across our key franchises in both developed and emerging markets” said Robert L. Parkinson, Jr., chairman and chief executive officer. “This provides a strong global foundation as we continue to improve our competitive position and performance, enhance operational, commercial and scientific effectiveness, meet challenges posed by the global marketplace, and create value for patients, healthcare providers, and other key stakeholders.”

Six-Month Results

For the first six months of 2014, Baxter reported net income of $1.1 billion, or $1.96 per diluted share, compared to net income of $1.1 billion and earnings per diluted share of $2.07 reported in 2013. Excluding special items, Baxter’s adjusted net income for the six-month period increased 7 percent to $1.3 billion, and earnings per diluted share of $2.45 also increased 7 percent from $2.29 per diluted share reported in the comparable prior-year period.

Baxter’s worldwide sales for the six-month period totaled $8.2 billion and increased 15 percent (or 16 percent excluding the impact of foreign currency). Excluding the contribution of Gambro revenues of $808 million, Baxter’s worldwide sales rose 4 percent (or 5 percent excluding the impact of foreign currency).

BioScience sales of $3.4 billion increased 6 percent (foreign currency had no impact on sales growth), while Medical Products sales of $4.9 billion advanced

 

- more -


BAXTER REPORTS 2nd QUARTER FINANCIAL RESULTS — Page  4

 

23 percent (or 24 percent excluding the impact of foreign currency) from the prior-year period. Excluding the contribution of Gambro revenues, Medical Products sales grew 3 percent (or 4 percent excluding the impact of foreign currency).

In the first half of 2014, Baxter generated cash flows from operations of approximately $1.2 billion and returned approximately $1.0 billion to shareholders through share repurchases of $450 million (or approximately 6 million shares) and dividends totaling $531 million (reflecting more than a 8 percent increase in dividend payments versus the prior-year period).

Recent Highlights

“During the quarter, Baxter announced a number of new product pipeline achievements and approvals, advanced collaborations, and marked progress towards our separation into two leading healthcare companies,” continued Parkinson. “We remain on track to complete the separation by mid-year 2015.”

Recent highlights include:

 

   

Global expansion of ADVATE, including European approval of a new production facility in Singapore, new multi-year tender awards in Australia and the UK, and new regulatory approvals in Turkey and Russia. ADVATE is now approved in 62 countries.

 

   

Approval from the U.S. Food and Drug Administration (FDA) of BAXJECT III reconstitution system with ADVATE, reducing the number of steps in the reconstitution process for patients and caregivers.

 

   

European CE marking of myPKFiT, a new web-based individualized dosing device for prophylactic treatment of hemophilia A with ADVATE. The device allows physicians to calculate personalized ADVATE treatment regimens based on patient information and individual pharmacokinetic (PK) profiles.

 

   

Completion of dosing in the Phase III clinical trial of BAX 855, an investigational extended half-life, recombinant factor VIII treatment for hemophilia A. The ongoing trial is aimed at assessing the efficacy of BAX

 

- more -


BAXTER REPORTS 2nd QUARTER FINANCIAL RESULTS — Page  5

 

 

855, and will also evaluate its safety and pharmacokinetic profile. Top line data is expected to be announced in the third quarter.

 

   

Presentation of a range of data on the company’s bleeding disorder pipeline during the World Federation of Hemophilia World Congress in Australia, including studies on BAX 855, ADVATE, OBI-1, BAX 111 and BAX 930.

 

   

510(k) clearance from the FDA for Baxter’s next-generation SIGMA Spectrum Infusion Pump with Master Drug Library.

 

   

Presentation of data supporting the safety and efficacy of the VIVIA hemodialysis system at the European Renal Association and European Dialysis and Transplant Association (ERA-EDTA). The VIVIA system, which completed the CE marking in Europe late last year, is being introduced on a limited basis in select European dialysis clinics in 2014.

 

   

Initiation of Phase 3 trials for CHS-0214, an investigational etanercept biosimilar, in rheumatoid arthritis and chronic plaque psoriasis, by Baxter’s partner Coherus BioSciences.

 

   

Announcement by Baxter’s partner, CTI BioPharma, of the completion of enrollment in its PERSIST-1 pivotal trial of pacritinib for patients with myelofibrosis.

 

   

Acquisition of AesRx, including its sickle cell disease development program, Aes-103. The investigational treatment, which is currently being evaluated in a Phase 2 clinical trial, has the potential to address an extremely high unmet clinical need in a community with inadequate treatment options and no recent major clinical developments.

 

   

Naming of several key executives, including the chief financial officers for both the new biopharmaceutical and medical products companies and the new head of research and development for BioScience.

Outlook for Third Quarter and Full-Year 2014

Baxter also announced today its guidance for the third quarter and confirmed its guidance for the full year.

For the third quarter of 2014, the company expects sales growth of approximately 12 to 13 percent, excluding the impact of foreign currency. Baxter

 

- more -


BAXTER REPORTS 2nd QUARTER FINANCIAL RESULTS — Page  6

 

expects earnings, before special items, of $1.28 to $1.32 per diluted share in the third quarter.

Baxter now expects sales growth for full-year 2014 of 10 to 11 percent, before the impact of foreign exchange. Also for the full year, Baxter expects earnings, before special items, of $5.10 to $5.20 per diluted share and cash flows from operations of approximately $3.5 billion, excluding cash costs related to the spin-off of the biopharmaceutical business.

The third quarter 2014 earnings guidance excludes approximately $0.07 per diluted share of projected intangible asset amortization expense. The full-year 2014 earnings guidance excludes the $0.62 per diluted share of special items comprising $0.49 per diluted share of items recorded in the first half of the year, and projected intangible asset amortization expense of $0.13 per diluted share for the remainder of the year. Reconciling for the inclusion of these items results in GAAP (Generally Accepted Accounting Principles) earnings of $4.48 to $4.58 per diluted share for the full-year 2014.

A webcast of Baxter’s second quarter conference call for investors can be accessed live from a link on the company’s website at www.baxter.com beginning at 7:30 a.m. CDT on July 17, 2014. Please visit Baxter’s website for more information regarding this and future investor events and webcasts.

Baxter International Inc., through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices,

 

- more -


BAXTER REPORTS 2nd QUARTER FINANCIAL RESULTS — Page  7

 

pharmaceuticals and biotechnology to create products that advance patient care worldwide.

This release includes forward-looking statements concerning the company’s financial results, business development activities, capital structure, R&D pipeline including results of clinical trials and planned product launches, outlook for 2014 and the planned separation of Baxter’s biopharmaceutical and medical products businesses and the expected leadership of the two resulting companies after the separation. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: demand for and market acceptance of risks for new and existing products; future actions of regulatory bodies and other governmental authorities, including the FDA and foreign counterparts; product quality or patient safety concerns leading to product recalls, withdrawals, launch delays, litigation, or declining sales; U.S. healthcare reform and other global austerity measures; reimbursement and rebate policies of government agencies and private payers; product development risks; the ability to successfully separate the biopharmaceutical and medical products businesses on the terms or timeline currently contemplated, if at all, and achieve the intended results; accurate identification of business development and R&D opportunities and realization of anticipated benefits, including the ability to successfully integrate the Gambro business and achieve anticipated efficiencies; timely submission and approval of regulatory filings; inventory reductions or fluctuations in buying patterns; the impact of geographic and product mix on the company’s sales; the impact of competitive products and pricing, including generic competition, drug reimportation and disruptive technologies; the availability of acceptable raw materials and component supply; fluctuations in supply and demand and the pricing of plasma-based therapies; the ability to enforce company patents; patents of third parties preventing or restricting the company’s manufacture, sale or use of affected products or technology; the impact of global economic conditions on Baxter and its customers, including foreign governments; foreign currency fluctuations and other risks identified in Baxter’s most recent filing on Form 10-K and other Securities and Exchange Commission filings, all of which are available on Baxter’s website. Baxter does not undertake to update its forward-looking statements.

# # #

 


BAXTER — PAGE  8

 

BAXTER INTERNATIONAL INC.

Consolidated Statements of Income

Three Months Ended June 30, 2014 and 2013

(unaudited)

(in millions, except per share and percentage data)

 

                                                        
    Three Months Ended
June 30,
       
    2014     2013     Change  

NET SALES

    $   4,264        $  3,669        16%   

COST OF SALES

    2,223        1,730        28%   
     

 

 

GROSS MARGIN

    2,041       1,939       5%   

 

 

% of Net Sales

    47.9%       52.8%        (4.9 pts

MARKETING AND ADMINISTRATIVE EXPENSES

    998        838        19%   

% of Net Sales

    23.4%       22.8%       0.6 pts   

RESEARCH AND DEVELOPMENT EXPENSES

    325        273        19%   

% of Net Sales

    7.6%       7.4%       0.2 pts   

NET INTEREST EXPENSE

    42       17       N/M   

OTHER EXPENSE, NET

    15        68        N/M   
     

 

 

PRE-TAX INCOME

    661       743        (11%

 

 

INCOME TAX EXPENSE

    141        153        (8%

 

 

% of Pre-Tax Income

    21.3%       20.6%       0.7 pts   

NET INCOME

    $     520       $     590        (12%

 

 

BASIC EPS

    $    0.96       $    1.09        (12%

 

 

DILUTED EPS

    $    0.95       $    1.07        (11%

 

 

WEIGHTED-AVERAGE NUMBER OF COMMON SHARES OUTSTANDING

     

Basic

    542       543    

Diluted

    548       549    

 

 

ADJUSTED PRE-TAX INCOME (excluding special items)

    $     885  A      $     844  A      5%   

ADJUSTED NET INCOME (excluding special items)

    $     692  A      $     659  A      5%   

ADJUSTED DILUTED EPS (excluding special items)

    $    1.26  A      $    1.20  A      5%   

 

A 

Refer to page 9 for a description of the adjustments and a reconciliation to generally accepted accounting principles (GAAP) measures.


BAXTER — PAGE  9

 

BAXTER INTERNATIONAL INC.

Note to Consolidated Statements of Income

Three Months Ended June 30, 2014 and 2013

Description of Adjustments and Reconciliation of GAAP to Non-GAAP Measures

(unaudited)

(in millions, except per share and percentage data)

The company’s GAAP results for the three months ended June 30, 2014 and 2013 included special items which impacted the GAAP measures as follows:

 

                                                        
    Three Months Ended
June  30,
       
    2014     2013     Change  

Gross Margin

    $  2,041        $    1,939        5%   

Intangible asset amortization expense 1

    47        25     

Business optimization items 2

    (14     (20  

Product-related items 3

    89            
 

 

 

 

Adjusted Gross Margin

    $  2,163        $    1,944        11%   
 

 

 

 

% of Net Sales

    50.7%        53.0%        (2.3 pts

Marketing and Administrative Expenses

    $     998        $       838        19%   

Gambro acquisition and integration items 4

    (27     (23  

Separation-related costs 6

    (22         

Business optimization items 2

    16            

Product-related items 3

    (4         
 

 

 

 

Adjusted Marketing and Administrative Expenses

    $     961        $       815        18%   
 

 

 

 

% of Net Sales

    22.5%        22.2%        0.3 pts   

Research and Development Expenses

    $     325        $       273        19%   

Business optimization items 2

    2        (18  

Business development items 5

    (35         
 

 

 

 

Adjusted Research and Development Expenses

    $     292        $       255        15%   
 

 

 

 

% of Net Sales

    6.8%        7.0%        (0.2 pts

Other Expense, Net

    $       15        $         68        N/M   

Reserve items and adjustments 7

    (30         

Gambro acquisition and integration items 4

    (2     (55  
 

 

 

 

Adjusted Other (Income) Expense, Net

    $      (17     $         13        N/M   
 

 

 

 

Pre-Tax Income

    $     661        $       743        (11%

Impact of special items

    224        101     
 

 

 

 

Adjusted Pre-Tax Income

    $     885        $       844        5%   
 

 

 

 

Income Tax Expense

    $     141        $       153        (8%

Impact of special items

    52        32     
 

 

 

 

Adjusted Income Tax Expense

    $     193        $       185        4%   
 

 

 

 

% of Adjusted Pre-Tax Income

    21.8%        21.9%        (0.1 pts

Net Income

    $     520        $       590        (12%

Impact of special items

    172        69     
 

 

 

 

Adjusted Net Income

    $     692        $       659        5%   
 

 

 

 

Diluted EPS

    $    0.95        $      1.07        (11%

Impact of special items

    0.31        0.13     
 

 

 

 

Adjusted Diluted EPS

    $    1.26        $      1.20        5%   
 

 

 

 

WEIGHTED-AVERAGE NUMBER OF COMMON SHARES OUTSTANDING

     

Diluted

    548        549     

 

 

 

1 

Effective January 1, 2014, Baxter has updated its non-GAAP measures above to exclude intangible asset amortization expense. Prior period non-GAAP measures have been revised to reflect the updated measures. Intangible asset amortization expense totaled $47 million ($36 million, or $0.07 per diluted share, on an after-tax basis) and $25 million ($20 million, or $0.04 per diluted share, on an after-tax basis) in 2014 and 2013, respectively.

 

2 

The company’s results in 2014 included a net benefit of $32 million ($18 million, or $0.03 per diluted share, on an after-tax basis) primarily related to an adjustment to a previous business optimization reserve that is no longer probable of being utilized. The company’s results in 2013 included a benefit of $20 million ($14 million, or $0.03 per diluted share, on an after-tax basis) related to an adjustment to a previous business optimization reserve that is no longer probable of being utilized, which was partially offset by additional business optimization charges of $18 million ($14 million, or $0.03 per diluted share, on an after-tax basis).

 

3 

The company’s results in 2014 included total charges of $93 million ($58 million, or $0.10 per diluted share, on an after-tax basis) principally related to product remediation efforts for the SIGMA Spectrum Infusion Pump.

 

4 

The company’s results in 2014 included total charges of $29 million ($21 million, or $0.04 per diluted share, on an after-tax basis) principally related to the acquisition and integration of Gambro AB (Gambro). The company’s results in 2013 included total charges of $78 million ($49 million, or $0.09 per diluted share, on an after-tax basis) primarily related to pre-acquisition costs for the planned acquisition of Gambro and losses on derivative instruments entered into during December 2012 and the first six months of 2013 to hedge the anticipated foreign currency cash outflows for the planned acquisition of Gambro.

 

5 

The company’s results in 2014 included a charge of $35 million ($30 million, or $0.05 per diluted share, on an after-tax basis) primarily related to certain milestone payments associated with the company’s collaboration arrangements.

 

6 

The company’s results in 2014 included separation-related costs of $22 million ($21 million, or $0.04 per diluted share, on an after-tax basis) for the planned separation of Baxter’s biopharmaceutical and medical products businesses.

 

7 

The company’s results in 2014 included a net expense of $30 million ($24 million, or $0.04 per diluted share, on an after-tax basis) primarily due to an increase in the estimated fair value of acquisition-related contingent payment liabilities, partially offset by a third-party recovery on previous litigation reserves.

For more information on the company’s use of non-GAAP financial measures in this press release, please see the company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on the date of this press release.


BAXTER — PAGE  10

 

BAXTER INTERNATIONAL INC.

Consolidated Statements of Income

Six Months Ended June 30, 2014 and 2013

(unaudited)

(in millions, except per share and percentage data)

 

                                                        
    Six Months Ended
June 30,
       
    2014     2013     Change  

NET SALES

    $   8,215        $   7,117        15%   

COST OF SALES

    4,213        3,422        23%   
     

 

 

GROSS MARGIN

    4,002       3,695       8%   

 

 

% of Net Sales

    48.7%       51.9%       (3.2 pts

MARKETING AND ADMINISTRATIVE EXPENSES

    1,918        1,633        17%   

% of Net Sales

    23.3%       22.9%       0.4 pts   

RESEARCH AND DEVELOPMENT EXPENSES

    638        519        23%   

% of Net Sales

    7.8%       7.3%       0.5 pts   

NET INTEREST EXPENSE

    85       42       N/M   

OTHER (INCOME) EXPENSE, NET

    (9 )      65        N/M   
     

 

 

PRE-TAX INCOME

    1,370       1,436       (5%

 

 

INCOME TAX EXPENSE

    294        294        0%   

 

 

% of Pre-Tax Income

    21.5%       20.5%       1 pts   

NET INCOME

    $  1,076       $   1,142       (6%

 

 

BASIC EPS

    $    1.98       $     2.10       (6%

 

 

DILUTED EPS

    $    1.96       $     2.07       (5%

 

 

WEIGHTED-AVERAGE NUMBER OF COMMON SHARES OUTSTANDING

     

Basic

    542       543    

Diluted

    548       550    

 

 

ADJUSTED PRE-TAX INCOME (excluding special items)

    $ 1,714  A       $  1,607  A      7%   

ADJUSTED NET INCOME (excluding special items)

    $ 1,344  A       $  1,260  A      7%   

ADJUSTED DILUTED EPS (excluding special items)

    $   2.45  A       $    2.29  A      7%   

 

A 

Refer to page 11 for a description of the adjustments and a reconciliation to GAAP measures.


BAXTER — PAGE  11

 

BAXTER INTERNATIONAL INC.

Note to Consolidated Statements of Income

Six Months Ended June 30, 2014 and 2013

Description of Adjustments and Reconciliation of GAAP to Non-GAAP Measures

(unaudited)

(in millions, except per share and percentage data)

The company’s GAAP results for the six months ended June 30, 2014 and 2013 included special items which impacted the GAAP measures as follows:

 

                                                        
    Six Months Ended
June 30,
       
    2014     2013     Change  

Gross Margin

    $  4,002        $   3,695        8%   

Intangible asset amortization expense 1

    90        50     

Business optimization items 2

    (2     (20  

Product-related items 3

    89            

Gambro acquisition and integration items 4

           1     
 

 

 

 

Adjusted Gross Margin

    $  4,179        $   3,726        12%   
 

 

 

 

% of Net Sales

    50.9%        52.4%        (1.5 pts

Marketing and Administrative Expenses

    $  1,918        $   1,633        17%   

Gambro acquisition and integration items 4

    (44     (40  

Reserve items and adjustments 6

    10            

Separation-related costs 7

    (22         

Business optimization items 2

    6            

Product-related items 3

    (4         
 

 

 

 

Adjusted Marketing and Administrative Expenses

    $  1,864        $   1,593        17%   
 

 

 

 

% of Net Sales

    22.7%        22.4%        0.3 pts   

Research and Development Expenses

    $     638        $      519        23%   

Business optimization items 2

    (4     (18  

Business development items 5

    (60         
 

 

 

 

Adjusted Research and Development Expenses

    $     574        $      501        15%   
 

 

 

 

% of Net Sales

    7.0%        7.0%        0 pts   

Other (Income) Expense, Net

    $        (9     $        65        N/M   

Reserve items and adjustments 6

    (30         

Gambro acquisition and integration items 4

    (19     (82  
 

 

 

 

Adjusted Other Income, Net

    $      (58     $       (17     N/M   
 

 

 

 

Pre-Tax Income

    $  1,370        $   1,436        (5%

Impact of special items

    344        171     
 

 

 

 

Adjusted Pre-Tax Income

    $  1,714        $   1,607        7%   
 

 

 

 

Income Tax Expense

    $     294        $      294        0%   

Impact of special items

    76        53     
 

 

 

 

Adjusted Income Tax Expense

    $     370        $      347        7%   
 

 

 

 

% of Adjusted Pre-Tax Income

    21.6%        21.6%        0 pts   

Net Income

    $  1,076        $  1,142        (6%

Impact of special items

    268        118     
 

 

 

 

Adjusted Net Income

    $  1,344        $   1,260        7%   
 

 

 

 

Diluted EPS

    $    1.96        $     2.07        (5%

Impact of special items

    0.49        0.22     
 

 

 

 

Adjusted Diluted EPS

    $    2.45        $     2.29        7%   
 

 

 

 

WEIGHTED-AVERAGE NUMBER OF COMMON SHARES OUTSTANDING

     

Diluted

    548        550     

 

 

 

1 

Effective January 1, 2014, Baxter has updated its non-GAAP measures above to exclude intangible asset amortization expense. Prior period non-GAAP measures have been revised to reflect the updated measures. Intangible asset amortization expense totaled $90 million ($70 million, or $0.13 per diluted share, on an after-tax basis) and $50 million ($40 million, or $0.07 per diluted share, on an after-tax basis) in 2014 and 2013, respectively.

 

2 

The company’s results in 2014 included a net benefit of $4 million (net charge of $3 million, or $0.01 per diluted share, on an after-tax basis) primarily related to an adjustment of $37 million to a previous business optimization reserve that is no longer probable of being utilized, partially offset by additional business optimization charges of $33 million. The company’s results in 2013 included a benefit of $20 million ($14 million, or $0.03 per diluted share, on an after-tax basis) related to an adjustment to a previous business optimization reserve that is no longer probable of being utilized, which was partially offset by additional business optimization charges of $18 million ($14 million, or $0.03 per diluted share, on an after-tax basis).

 

3 

The company’s results in 2014 included total charges of $93 million ($58 million, or $0.10 per diluted share, on an after-tax basis) principally related to product remediation efforts for the SIGMA Spectrum Infusion Pump.

 

4 

The company’s results in 2014 included total charges of $63 million ($47 million, or $0.09 per diluted share, on an after-tax basis) principally related to the acquisition and integration of Gambro, including a loss on the divestiture of Baxter’s legacy Continuous Renal Replacement Therapy business. The company’s results in 2013 included total charges of $123 million ($78 million, or $0.15 per diluted share, on an after-tax basis) primarily related to pre-acquisition costs for the planned acquisition of Gambro and losses on derivative instruments entered into in December 2012 and the first six months of 2013 to hedge the anticipated foreign currency cash outflows associated with the planned acquisition of Gambro.

 

5 

The company’s results in 2014 included charges of $60 million ($52 million, or $0.09 per diluted share, on an after-tax basis) related to certain milestone payments associated with the company’s collaboration arrangements.

 

6 

The company’s results in 2014 included a net expense of $20 million ($17 million, or $0.03 per diluted share, on an after-tax basis) primarily related to an increase in the estimated fair value of acquisition-related contingent payment liabilities, partially offset by third-party recoveries and reversals of prior litigation reserves.

 

7 

The company’s results in 2014 included separation-related costs of $22 million ($21 million, or $0.04 per diluted share, on an after-tax basis) for the planned separation of Baxter’s biopharmaceutical and medical products businesses.

For more information on the company’s use of non-GAAP financial measures in this press release, please see the company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on the date of this press release.


BAXTER — PAGE  12

 

BAXTER INTERNATIONAL INC.

Cash Flows from Operations and Changes in Net Debt

(unaudited)

($ in millions)

 

                                                                           

 Cash Flows from Operations

  

   (Brackets denote cash outflows)   Three Months Ended
June 30,
    Six Months Ended
June 30,
 
    2014     2013     2014     2013  

   Net income

    $    520        $   590        $1,076        $1,142   

   Adjustments

       

   Depreciation and amortization

    253       183        489       366   

   Deferred income taxes

    (14 )      (101     (31 )      (63

   Stock compensation

    41       40        72       72   

   Realized excess tax benefits from stock issued under employee benefit plans

    (5 )     (7     (17 )     (19

   Business optimization charges

    (32 )     (2     (4 )     (2

   Net periodic pension benefit and OPEB costs

    70       93        141       187   

   Infusion pump and other product-related charges

    93              93         

   Other

    93        44        78        54   

   Changes in balance sheet items

       

   Accounts and other current receivables, net

    (230 )     (73     3       12   

   Inventories

    (127 )     (125     (360 )     (306

   Accounts payable and accrued liabilities

    14       128        (222 )     (171

   Business optimization and infusion pump payments

    (38 )     (26     (83 )     (52

   Other

    (39 )      19        (77 )      (71

 

 

   Cash flows from operations

    $   599       $   763        $1,158       $1,149   

 

 
       

 Changes in Net Debt

  

    Increase (decrease)   Three Months Ended
June 30,
    Six Months Ended
June 30,
 
    2014     2013     2014     2013  

   Net debt, beginning of period A

    $6,645       $3,178        $6,433       $2,660   

   Cash flows from operations

    (599 )     (763     (1,158 )     (1,149

   Capital expenditures

    423       347        844       639   

   Dividends

    265       244        531       490   

   Proceeds from stock issued under employee benefit plans

    (106 )     (138     (232 )     (322

   Purchases of treasury stock

    200       183        450       717   

   Acquisitions and investments

    117        20        176        87   

   Sales of investments and other investing activities

    2               (94 )      (10

   Other, including the effect of exchange rate changes

    26        (25     23        (66

 Increase (decrease) in net debt

    328       (132     540       386   

   Net debt, June 30 A

    $6,973       $3,046        $6,973       $ 3,046   

 

 
       

 Key statistics, June 30:

                               

 Days sales outstanding

    56.7  B      53.5        56.7  B      53.5   

 Inventory turns

    2.2        2.2        2.2        2.2   

 

A 

Net debt is a non-GAAP measure, refer to page 13 for a description of net debt and a reconciliation to GAAP measures.

 

B 

Includes the impact from the acquisition of Gambro. Excluding Gambro, the company’s days sales outstanding was 53.1 days as of June 30, 2014.


BAXTER — PAGE  13

 

BAXTER INTERNATIONAL INC.

Total Debt to Net Debt Reconciliation

(unaudited)

($ in millions)

 

                                                                                                                 

 Total Debt to Net Debt Reconciliation A

  

    June 30,
2014
    March 31,
2014
    December 31,
2013
    June 30,
2013
    March 31,
2013
    December 31,
2012
 

   Short-term debt

    $     186        $       49        $     181        $       33        $     333        $       27   

   Current maturities of long-term debt and lease obligations

    1,125        1,128        859        378        377        323   

   Long-term debt and lease obligations

    7,528        7,517        8,126        8,624        5,157        5,580   

 

 

   Total debt

    8,839        8,694        9,166        9,035        5,867        5,930   

 

 

   Less: Cash and equivalents

    (1,866     (2,049     (2,733     (5,989     (2,689     (3,270

 

 

   Total net debt

    $  6,973        $  6,645        $  6,433        $  3,046        $  3,178        $  2,660   

 

 

 

A 

Net debt represents the difference between total debt (defined as short-term debt, current maturities of long-term debt and lease obligations, and long-term debt and lease obligations as presented on the company’s consolidated balance sheets) and cash and equivalents.

For more information on the company’s use of non-GAAP financial measures in this press release, please see the company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on the date of this press release.


BAXTER — PAGE  14

 

BAXTER INTERNATIONAL INC.

Net Sales

Periods Ending June 30, 2014 and 2013

(unaudited)

($ in millions)

 

                                                                                                                                                       
    

Q2

2014

    

Q2

2013

     % Growth @
Actual Rates
     % Growth @
Constant Rates
     YTD
2014
     YTD
2013
     % Growth @
Actual Rates
     % Growth @
Constant Rates    
 

    

                                                                      

BioScience

                        

United States

    $   835         $   782         7%         7%         $1,659         $1,555         7%         7%   

International

    916         856         7%         5%         1,700         1,613         5%         5%   

Total BioScience

    $1,751         $1,638         7%         6%         $3,359         $3,168         6%         6%   

    

                                                                      

Medical Products

                        

United States

    $   897         $   764         17%         17%         $1,733         $1,473         18%         18%   

International

    1,616         1,267         28%         28%         3,123         2,476         26%         28%   

Total Medical Products 1

    $2,513         $2,031         24%         24%         $4,856         $3,949         23%         24%   

    

                                                                      

Baxter International Inc.    

                        

United States

    $1,732         $1,546         12%         12%         $3,392         $3,028         12%         12%   

International

    2,532         2,123         19%         19%         4,823         4,089         18%         19%   

Total Baxter 1

    $4,264         $3,669         16%         16%         $8,215         $7,117         15%         16%   
                                                                        

 

Includes Gambro net sales of $408 million in the second quarter of 2014 and $808 million for the six months ended June 30, 2014. Medical Products net sales excluding Gambro grew 4% at both actual rates and constant rates during the second quarter of 2014. Total Baxter net sales excluding Gambro grew 5% at both actual rates and constant rates during the second quarter of 2014. Medical Products net sales excluding Gambro grew 3% at actual rates and 4% at constant rates for the six months ended June 30, 2014. Total Baxter net sales excluding Gambro grew 4% at actual rates and 5% at constant rates for the six months ended June 30, 2014.


BAXTER — PAGE  15

 

BAXTER INTERNATIONAL INC.

Sales by Franchise

Periods Ending June 30, 2014 and 2013

(unaudited)

($ in millions)

 

                                                                                                                                                       
     Q2
2014
     Q2
2013
     % Growth @
Actual Rates
    % Growth @
Constant Rates
    YTD
2014
     YTD
2013
     % Growth @
Actual Rates
    % Growth @
Constant Rates
 

    

                                                                   

BioScience

                       

Hemophilia

    $   904         $   849         6%        6%        $1,731         $1,614         7%        7%   

BioTherapeutics

    548         513         7%        6%        1,050         1,022         3%        2%   

BioSurgery

    189         178         6%        5%        365         350         4%        4%   

Vaccines

    110         98         12%        6%        213         182         17%        15%   

Total BioScience

    $1,751         $1,638         7%        6%        $3,359         $3,168         6%        6%   

    

                                                                   

Medical Products

                       

Fluid Systems

    $   816         $   755         8%        8%        $1,573         $1,495         5%        6%   

Renal 1

    1,044         654         60%        61%        2,035         1,244         64%        66%   

Specialty Pharmaceuticals

    404         366         10%        9%        771         729         6%        6%   

BioPharma Solutions

    249         256         (3%     (4%     477         481         (1%     0%   

Total Medical Products    

    $2,513         $2,031         24%        24%        $4,856         $3,949         23%        24%   

    

                                                                   

Total Baxter

    $4,264         $3,669         16%        16%        $8,215         $7,117         15%        16%   
                                                                     

 

1 

Consists of PD and HD therapies, and includes Gambro net sales of $408 million in the second quarter of 2014 and $808 million for the six months ended June 30, 2014. Renal sales excluding Gambro decreased by 3% at actual rates and 1% at constant rates during the second quarter of 2014. Renal sales excluding Gambro decreased by 1% at actual rates and grew by 1% at constant rates for the six months ended June 30, 2014.


BAXTER — PAGE  16

 

BAXTER INTERNATIONAL INC.

Franchise Sales by U.S. and International

Three-Month Periods Ending June 30, 2014 and 2013

(unaudited)

($ in millions)

 

                                                                                                                                                                          
    Q2 2014      Q2 2013      % Growth  
    U.S.      International      Total      U.S.      International      Total      U.S.     International      Total  

    

                                                                              

BioScience

                                                                              

Hemophilia

    $   375         $   529         $   904         $   346         $   503         $   849         8%        5%         6%   

BioTherapeutics

    358         190         548         335         178         513         7%        7%         7%   

BioSurgery

    102         87         189         101         77         178         1%        13%         6%   

Vaccines

            110         110                 98         98                12%         12%   

Total BioScience

    $   835         $   916         $1,751         $   782         $   856         $1,638         7%        7%         7%   

    

                                                                              

Medical Products

                                                                              

Fluid Systems

    $   443         $   373         $   816         $   390         $   365         $   755         14%        2%         8%   

Renal 1

    186         858         1,044         101         553         654         84%        55%         60%   

Specialty Pharmaceuticals

    174         230         404         163         203         366         7%        13%         10%   

BioPharma Solutions

    94         155         249         110         146         256         (15%     6%         (3%

Total Medical Products 1    

    $   897         $1,616         $2,513         $   764         $1,267         $2,031         17%        28%         24%   

    

                                                                              

Total Baxter 1

    $1,732         $2,532         $4,264         $1,546         $2,123         $3,669         12%        19%         16%   
                                                                                

 

Includes Gambro net sales of $408 million in the second quarter of 2014. Renal sales excluding Gambro decreased by 3% at actual rates and 1% at constant rates during the second quarter of 2014. Medical Products net sales excluding Gambro grew 4% at both actual rates and constant rates during the second quarter of 2014. Total Baxter net sales excluding Gambro grew 5% at both actual rates and constant rates during the second quarter of 2014.

GRAPHIC 4 g758846g44v50.jpg GRAPHIC begin 644 g758846g44v50.jpg M_]C_X``02D9)1@`!`@$!+`$L``#_X0G[17AI9@``34T`*@````@`!P$2``,` M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q M``(````4````<@$R``(````4````AH=I``0````!````G````,@```$L```` M`0```2P````!061O8F4@4&AO=&]S:&]P(#7U5F9VAI:FML;6YO8W1U=G=X>7 MI[?'U^?W$0`"`@$"!`0#!`4&!P<&!34!``(1`R$Q$@1!46%Q(A,%,H&1%*&Q M0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"TD235*,79$55-G1EXO*S MA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_ MV@`,`P$``A$#$0`_`/4,B^K&HLR+G;:JFE[W>#6B7%8/_C@?5+_N>W[G?W(? M^,7/.%]5,K:8?D%M#?'WGW_^![EY5]3\/`S.OXU?4G5MPVR^WU7!K2&C1DG] MYRVOAOPO#GY3+S.8S`QF7#''5RX(\4OF8YS((`?6?_'`^J7_`'/;]Q_N6OTS MJO3^JX_VGI][;ZI@N;V/[KA^:O*?\8M/U8QG8=/0F4-L.YU[L=VX1IL:Z"Y: MWU`/4>C?5O)ZE1A6YMN9']]0F>*C7T?2TER'_.[ZT?\`SLY/W_[%F5_XVZF9@Q\WI[Z&M?LN M.Z7,@[7>R/S%2A\*YR=\$(Y.$6?;R8IG_FS7<<1OH^A)+GOK5]:+N@X=&?5B M'+Q+='V!VW:7:U[OY+U1^JO^,+%Z_GNP;*/LEFPOJ)=(='TF_P":HH_#^9E@ M/,1AQ8HWQ2!CZ>'YKA\ZN(75ZO7I+E\OZ[,LZHWI?0<4]6O'\]96Z*J_ZUOT M5PGUZ^L_6?\`G!D8U&79CUT!C'54O(:'AH-GT?I>\JQRGPCF.8R#&:Q<4/=] M?S<'RZX_GCQ?H\2)3`%[OL:2\_\`JM]8/K+B].Q,-_1LK*WF79ECB9#W3ZFY M_P"8UKD7K/\`C4P\#J%N%BXCLEM#BQUN[:"YIAVQ-/PGFCFEBQ1&7AOU0E"N M&)X>*7J]'%_63QQJSH]VDN#S/\8W5<&AN3F="NHIL@,L>2&F=1^:KO3O\8N# MG]$SNHMH=7=T]@?90XCW;CM9L?\`UDV7POG(Q$_;XHF0AQ0E"8XY'@C\DOWE M<<>[UZ2\]PO\;'VJXTLZ7;8\M)8RH[W%P[;0U;/U?^M_4NK=2&'?TB["9L+W M76`@"./I-;])++\+YS%&4LF,0$!Q&YX_E\N)0G$[%__0L_XX.I:X/3&GC=?8 M/C^CK_[^L[_%Y]3NF]Y2'PZ'+8^:^[YJ$ MIY(PR2,92EQS'I_Q&$QD9V8V'@OK-C8&%U[+Q>FR,6A^RN3N,@#?[OZZZ?ZT M_6OK6)TWI/3:;G8MWV5EV2ZKV%Q?_--]OT?8%K8_^*#';D,LR<]UM0<'6,#( M+A,EN[=^UDZ[M MS?I;5Q'2\1_5.M8V*YQL?E7M:YYY.YWO<5Z91_BWSJ\5V"[K5YPRTM%#1#9/ MEN^BI?5__%FSHW5J.I',]?T"2*RR-2"V9W>:&/XMRV*/,R&>,I3XON\<>(XN M$>K@@9<$?^DZ^SI#>B9&/U1[:<%U>QSG=H^AL_EM_,7@1<:+W&E M[@`3L>):2W][^TU>T9GU*LZMU5N;US-=F8U1)JPFM].L>`.T^Y!^M'^+O#Z[ MDTY%%HPC57Z3FL8"'`?S?[OT%6^$_$.5Y*\<\LL@S>O)(1E[.&0VC&/#[DY3 M_3FNG&4M:V;OU1=T/'^K->;TNH54^F7W=WE[!^D%K_SG+QZD6=:^L+`XR[-R M1)/@]_\`Y%>N_5;ZG6]`IR<2S,^UX>4V'4ENV"?:YP,_G,6&?\4S*LW[3@]1 M?C['[Z?9+F0=S??/YJ=R//]7LYI1G+3U>F?Z?I5*,B(Z;;A[? M.O9T[I5]_#<6ESA'\AOM7@73,/,ZKU6G&QX?E9%DMW_1+OIG>O9\'ZM]4!NK MZOU:SJ.+=4ZIU#FA@]VF^6KGJ?\`%0[$S!E8'5;*'UNW5/#!N;_:E,^%MU8=>3U-[OL=987O9N<][CN?:[5.Y?XCCA+'CGFP#EA/W)QP8L MN/U0_60^:/\`G.!1A=FC?B7G?\4/3_4ZAF=0<-*&"MA_E/\`I?\`1"]46%]4 M?JNSZM8-N*+OM!NL]0OV[3P&AJW5F?%N:CS/.9,L#Q8](P/]6(7PC40'_]'U M1)?*R22GZI27RLDDI^J4E\K))*?JE)?*R22GZI27RLDDI^J4E\K))*?JE)?* MR22GZI27RLDDI__9_^T.CE!H;W1O'1)D%L:6=N96YU;0````]%4VQI8V5(;W)Z06QI9VX````'9&5F875L M=`````EV97)T06QI9VYE;G5M````#T53;&EC959E7!E96YU;0```!%%4VQI8V5"1T-O;&]R5'EP90`` M``!.;VYE````"71O<$]U='-E=&QO;F<`````````"FQE9G1/=71S971L;VYG M``````````QB;W1T;VU/=71S971L;VYG``````````MR:6=H=$]U='-E=&QO M;F<``````#A"24T$%```````!`````(X0DE-!`P`````".D````!````@``` M`",```&````T@```",T`&``!_]C_X``02D9)1@`!`@$`2`!(``#_[0`,061O M8F5?0TT``?_N``Y!9&]B90!D@`````'_VP"$``P("`@)"`P)"0P1"PH+$14/ M#`P/%1@3$Q43$Q@1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P, M#`P!#0L+#0X-$`X.$!0.#@X4%`X.#@X4$0P,#`P,$1$,#`P,#`P1#`P,#`P, M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#/_``!$(`",`@`,!(@`"$0$#$0'_W0`$ M``C_Q`$_```!!0$!`0$!`0`````````#``$"!`4&!P@)"@L!``$%`0$!`0$! M``````````$``@,$!08'"`D*"Q```00!`P($`@4'!@@%`PPS`0`"$0,$(1(Q M!4%181,B<8$R!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S-1:BLH,F1)-4 M9$7"HW0V%])5XF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6 MYO8W1U=G=X>7I[?'U^?W$0`"`@$"!`0#!`4&!P<&!34!``(1`R$Q$@1!46%Q M(A,%,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"TD235*,7 M9$55-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S=' M5V=WAY>GM\?_V@`,`P$``A$#$0`_`/4,B^K&HLR+G;:JFE[W>#6B7%8/_C@? M5+_N>W[G?W(?^,7/.%]5,K:8?D%M#?'WGW_^![EY5]3\/`S.OXU?4G5MPVR^ MWU7!K2&C1DG]YRVOAOPO#GY3+S.8S`QF7#''5RX(\4OF8YS((`?6?_'`^J7_ M`'/;]Q_N6OTSJO3^JX_VGI][;ZI@N;V/[KA^:O*?\8M/U8QG8=/0F4-L.YU[ ML=VX1IL:Z"Y:WU`/4>C?5O)ZE1A6YMN9']]0F>*C7T?2TER'_.[ZT?\`SLY/W_[%F5_XVZF9 M@Q\WI[Z&M?LN.Z7,@[7>R/S%2A\*YR=\$(Y.$6?;R8IG_FS7<<1OH^A)+GOK M5]:+N@X=&?5B'+Q+='V!VW:7:U[OY+U1^JO^,+%Z_GNP;*/LEFPOJ)=(='TF M_P":HH_#^9E@/,1AQ8HWQ2!CZ>'YKA\ZN(75ZO7I+E\OZ[,LZHWI?0<4]6O' M\]96Z*J_ZUOT5PGUZ^L_6?\`G!D8U&79CUT!C'54O(:'AH-GT?I>\JQRGPCF M.8R#&:Q<4/=]?S<'RZX_GCQ?H\2)3`%[OL:2\_\`JM]8/K+B].Q,-_1LK*WF M79ECB9#W3ZFY_P"8UKD7K/\`C4P\#J%N%BXCLEM#BQUN[:"YIAVQ-/PGFCFE MBQ1&7AOU0E"N&)X>*7J]'%_63QQJSH]VDN#S/\8W5<&AN3F="NHIL@,L>2&F M=1^:KO3O\8N#G]$SNHMH=7=T]@?90XCW;CM9L?\`UDV7POG(Q$_;XHF0AQ0E M"8XY'@C\DOWE<<>[UZ2\]PO\;'VJXTLZ7;8\M)8RH[W%P[;0U;/U?^M_4NK= M2&'?TB["9L+W76`@"./I-;])++\+YS%&4LF,0$!Q&YX_E\N)0G$[%__0L_XX M.I:X/3&GC=?8/C^CK_[^L[_%Y]3NF]Y2' MPZ'+8^:^[YJ$IY(PR2,92EQS'I_Q&$QD9V8V'@OK-C8&%U[+Q>FR,6A^RN3N M,@#?[OZZZ?ZT_6OK6)TWI/3:;G8MWV5EV2ZKV%Q?_--]OT?8%K8_^*#';D,L MR<]UM0<'6,#(+A,EN[=^UDZ[MS?I;5Q'2\1_5.M8V*YQL?E7M:YYY.YWO<5Z91_BWSJ\5V"[K M5YPRTM%#1#9/EN^BI?5__%FSHW5J.I',]?T"2*RR-2"V9W>:&/XMRV*/,R&> M,I3XON\<>(XN$>K@@9<$?^DZ^SI#>B9&/U1[:<%U>QSG=H^AL_E MM_,7@1<:+W&E[@`3L>):2W][^TU>T9GU*LZMU5N;US-=F8U1)JPFM].L>`.T M^Y!^M'^+O#Z[DTY%%HPC57Z3FL8"'`?S?[OT%6^$_$.5Y*\<\LL@S>O)(1E[ M.&0VC&/#[DY3_3FNG&4M:V;OU1=T/'^K->;TNH54^F7W=WE[!^D%K_SG+QZD M6=:^L+`XR[-R1)/@]_\`Y%>N_5;ZG6]`IR<2S,^UX>4V'4ENV"?:YP,_G,6& M?\4S*LW[3@]1?C['[Z?9+F0=S??/YJ=R//]7LYI1G+3U>F?Z? MI5*,B(Z;;A[?.O9T[I5]_#<6ESA'\AOM7@73,/,ZKU6G&QX?E9%DMW_1+OIG M>O9\'ZM]4!NKZOU:SJ.+=4ZIU#FA@]VF^6KGJ?\`%0[$S!E8'5;*'UNW5/#! MN;_:E,^%MU8=>3U-[OL=987O9N<][CN?:[5.Y?XCCA+'CG MFP#EA/W)QP8LN/U0_60^:/\`G.!1A=FC?B7G?\4/3_4ZAF=0<-*&"MA_E/\` MI?\`1"]46%]4?JNSZM8-N*+OM!NL]0OV[3P&AJW5F?%N:CS/.9,L#Q8](P/] M6(7PC40'_]'U1)?*R22GZI27RLDDI^J4E\K))*?JE)?*R22GZI27RLDDI^J4 ME\K))*?JE)?*R22GZI27RLDDI__9`#A"24T$(0``````50````$!````#P!! M`&0`;P!B`&4`(`!0`&@`;P!T`&\`G)E4WI.5&-Z:V,Y9"<_ M/@H\/V%D;V)E+7AA<"UF:6QT97)S(&5S8STB0U(B/SX*/'@Z>&%P;65T82!X M;6QN#IX87!T:STG6$U0('1O;VQK:70@ M,BXX+C(M,S,L(&9R86UE=V]R:R`Q+C4G/@H\&%P34TZ1&]C=6UE;G1)1#YA M9&]B93ID;V-I9#IP:&]T;W-H;W`Z93@P9&0X-38M9C$Y,RTQ,64P+3@X,&$M M83-E-#@Y-#1B9C,P/"]X87!-33I$;V-U;65N=$E$/@H@/"]R9&8Z1&5S8W)I M<'1I;VX^"@H\+W)D9CI21$8^"CPO>#IX87!M971A/@H@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`* M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*/#]X<&%C:V5T(&5N M9#TG=R<_/O_B#%A)0T-?4%)/1DE,10`!`0``#$A,:6YO`A```&UN=')21T(@ M6%E:(`?.``(`"0`&`#$``&%C'0`````0V]P>7)I9VAT("AC*2`Q.3DX($AE=VQE='0M4&%C:V%R9"!# M;VUP86YY``!D97-C`````````!)S4D="($E%0S8Q.38V+3(N,0`````````` M````$G-21T(@245#-C$Y-C8M,BXQ```````````````````````````````` M``````````````````````````````````!865H@````````\U$``0````$6 MS%A96B``````````````````````6%E:(````````&^B```X]0```Y!865H@ M````````8ID``+>%```8VEA96B`````````DH```#X0``+;/9&5S8P`````` M```6245#(&AT='`Z+R]W=W`&,`:`!M`'(` M=P!\`($`A@"+`)``E0":`)\`I`"I`*X`L@"W`+P`P0#&`,L`T`#5`-L`X`#E M`.L`\`#V`/L!`0$'`0T!$P$9`1\!)0$K`3(!.`$^`44!3`%2`5D!8`%G`6X! M=0%\`8,!BP&2`9H!H0&I`;$!N0'!`$!Z0'R`?H"`P(,`A0"'0(F M`B\".`)!`DL"5`)=`F<"<0)Z`H0"C@*8`J("K`*V`L$"RP+5`N`"ZP+U`P`# M"P,6`R$#+0,X`T,#3P-:`V8#<@-^`XH#E@.B`ZX#N@/'`],#X`/L`_D$!@03 M!"`$+00[!$@$501C!'$$?@2,!)H$J`2V!,0$TP3A!/`$_@4-!1P%*P4Z!4D% M6`5G!7<%A@66!:8%M07%!=4%Y07V!@8&%@8G!C<&2`99!FH&>P:,!IT&KP;` M!M$&XP;U!P<'&09!ZP'OP?2!^4'^`@+"!\(,@A&"%H( M;@B"")8(J@B^"-((YPC["1`))0DZ"4\)9`EY"8\)I`FZ"<\)Y0G["A$*)PH] M"E0*:@J!"I@*K@K%"MP*\PL+"R(+.0M1"VD+@`N8"[`+R`OA"_D,$@PJ#$,, M7`QU#(X,IPS`#-D,\PT-#28-0`U:#70-C@VI#<,-W@WX#A,.+@Y)#F0.?PZ; M#K8.T@[N#PD/)0]!#UX/>@^6#[,/SP_L$`D0)A!#$&$0?A";$+D0UQ#U$1,1 M,1%/$6T1C!&J$)%ZX7TA?W&!L80!AE&(H8KQC5&/H9(!E%&6L9D1FW&=T:!!HJ M&E$:=QJ>&L4:[!L4&SL;8QN*&[(;VAP"'"H<4AQ['*,0!YJ'I0>OA[I'Q,?/A]I'Y0?OQ_J(!4@02!L()@@Q"#P(1PA2"%U M(:$ASB'[(B--@U$S5--8Y",$)R0K5"]T,Z0WU# MP$0#1$=$BD3.11)%546:1=Y&(D9G1JM&\$25^!8+UA]6,M9&EEI6;A:!UI66J9:]5M%6Y5;Y5PU7(9O5\/7V%?LV`%8%=@JF#\84]AHF'U8DEBG&+P8T-CEV/K9$!DE&3I M93UEDF7G9CUFDF;H9SUGDV?I:#]HEFCL:4-IFFGQ:DAJGVKW:T]KIVO_;%=L MKVT(;6!MN6X2;FMNQ&\>;WAOT7`K<(9PX'$Z<95Q\')+%V/G:;=OAW5G>S>!%X;GC,>2IYB7GG>D9ZI7L$>V-[PGPA?(%\ MX7U!?:%^`7YB?L)_(W^$?^6`1X"H@0J!:X'-@C""DH+T@U>#NH0=A("$XX5' MA:N&#H9RAM>'.X>?B`2(:8C.B3.)F8G^BF2*RHLPBY:+_(QCC,J-,8V8C?^. M9H[.CS:/GI`&D&Z0UI$_D:B2$9)ZDN.339.VE""4BI3TE5^5R98TEI^7"I=U ME^"83)BXF229D)G\FFB:U9M"FZ^<')R)G/>=9)W2GD">KI\=GXN?^J!IH-BA M1Z&VHB:BEJ,&HW:CYJ16I,>E.*6IIAJFBZ;]IVZGX*A2J,2I-ZFIJARJCZL" MJW6KZ:QK_U MP'#`[,%GP>/"7\+;PUC#U,11Q,[%2\7(QD;&P\=!Q[_(/%$XIZ#+HO.E&Z=#J6^KEZW#K^^R&[1'MG.XH M[K3O0._,\%CPY?%R\?_RC/,9\Z?T-/3"]5#UWO9M]OOWBO@9^*CY./G'^E?Z MY_MW_`?\F/TI_;K^2_[<_VW____N``Y!9&]B90!D0`````'_VP"$``$!`0$! M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$"`@("`@(" M`@("`@,#`P,#`P,#`P,!`0$!`0$!`0$!`0("`0("`P,#`P,#`P,#`P,#`P,# M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`__``!$(`",`@`,! M$0`"$0$#$0'_W0`$`!#_Q`&B````!@(#`0`````````````'"`8%!`D#"@(! M``L!```&`P$!`0````````````8%!`,'`@@!"0`*"Q```@$#!`$#`P(#`P," M!@EU`0(#!!$%$@8A!Q,B``@Q%$$R(Q4)44(6820S%U)Q@1ABD25#H;'P)C1R M"AG!T34GX5,V@O&2HD147J%AH>(B8J4E9:7F)F:I*6FIZBIJK2UMK>X MN;K$Q<;'R,G*U-76U]C9VN3EYN?HZ>KT]?;W^/GZ$0`"`0,"!`0#!00$!`8& M!6T!`@,1!"$2!3$&`"(305$',F$4<0A"@2.1%5*A8A8S";$DP=%#$A:.SP]/C\RD:E*2T MQ-3D])6EM<75Y?4H1U=F.':&EJ:VQM;F]F=WAY>GM\?7Y_=(6&AXB)BHN,C8 MZ/@Y25EI>8F9J;G)V>GY*CI*6FIZBIJJNLK:ZOK_V@`,`P$``A$#$0`_`-\+ M?V^=K]8[(W;V+O;*1879^Q]NYC=>Y\Q,KO%C,!@J*;(Y2OD6-6D=*6CIW_;-RQL-H;C>]PN8[>",4!DFE<)&@)Q5F(&>FYI4@BDFD-( MT4DGT`R>JE!_PH$_E,$7_P!FSVN/]?![D!_WG&^\S?\`DV_]\G_PC5W_`,YH M/^@^@[_7#E[_`*.*_L/^;KK_`*"!/Y3(L?\`9LMK_#^[? M^^4>'LQ>?\Y8/^@^O?UPY>_Z.*_L/^;JQ;XU?*KX_?+[KR+M3XY=G[;[2V4U M;-C:G*;?JF>3&9.GOYL9EJ"98JW&UR`7\CJRO[/<8OJ+*=9(JTJ/(^A].C">X MWZ6=>]^Z]U[W[KW7O?NO=>]^Z]UW8_T/^V/OW7NO$$?7W[KW77OW7NO>_=>Z M][]U[KWOW7NO>_=>Z__0V*O^%%/?51T1_*H[^?&Y".AS_;,^UNF,.!5?;551 M#O?+Q)N1:72RRRE-J4-:6"_1;D\>\_/[LGVZC]P_O@^W(NK8R;;LRS[G+VZE M!M(R8"WD*W#Q`5\^'06YRN_I-@N])H\E$'^V.?Y5Z^?Y_)]ZBZ$[M^?G2FVO ME+F.O,9T-B9W\'63XW;E979"MH(ICE%8!*I=2 M?Q[^D'[[7.GN+R!]W'GO=?:.QW.7W$G$4%F=O@>>XBDFE4/.J(KD>''K8MI( M!IU$/+EM:W6[VJ7[(+45+:S0$`8&?4]6:?\`"BO9O\L'K'(_'+8W\OS:O1>, MW)-#O/<7:.:Z.ST&X<<,9(N)I-LXC.U=!E,K0?>2S-/-$NL2*BFXL?>*?]V- MOGWL^;+;W0Y@^\CO',,VUJ;:&PBW:$POX@\1IY(E>.-](&A6--))'1[SE'L< M!LHMGCB#]Q8H:^E`T,;DZ+-;\$\\#P18"";(LAK-(68Q!%+`&V,O]X\OMI[^_>CY` M]IN8_=?9N5]BY:V"YEO]SN'1UBGN7C>.TH#4S,$!\.M5U%B!7HXY1^LVO9+J M^@L9)Y9I0%08J`#5OL^?5J7_``[?_-"_[T>?);_S^1__`%O]XB?\!I]TK_V? MSE3_`)PG_H/H^_K#OW_3+3_MZ(OMW_A6OM/#=OT?7'>OPZWIU?C\9N^3:/8U M9'N^#);DV+4TF0;%Y>6JVW-CJ>:KJ,%5H_W%,&64B-E7U6'O(+=/[FC>;[DF M?FGV]][K#=[F6Q%S9*;8QP7:LGB1A9P[!1*I&AZ%>X$XZ*D]PHUN5@N]M:,! MJ-FI7-#BGEZ=7(?S3?YHF]?Y=O3_`%=\A]I_'FJ[\Z1WV]+29[>&*W,<$^RZ MW/4E-D-H3Y2E:BJR,/N2EF9(ZAM"QU(6(^J10<'ONB?=*V/[S?.O-WMGO'N8 MG+G/FWAFAMI(/&^J6)F2Y6-@Z_JP,`2@J2E7&%/0EW[?I=FMH+R.S\:U?B0: M::\*_(^OKT5;^55_PH5ZP_F.]\9[H'8H]X2X:5 M),YA8'>GHEI:^AQ;-5J"3KBB>W(]R_\`>_\`[M3FW[KWMYMON/M?-_\`6'9C M?+;W0CMFB:V$H(BE(U-J1Y*1G&&9?7I!L'.,&]7;V;P>%)IJM36M.(_9GH6> MV/YU^*W-\G<7\2OY>O167^=O9%$L[=F[MV-N.##=2]9$3I21KG.P'I*K"-%2 MSE_NIQ*(4:-HT9Y+#V#>3ON'7FT^T]Y[S?>5]PH/;SE:2GT%O=P&7<;_``6/ MA6899:L*>&NG40P9@JYZ47',ZO?+MVS6INYQ\14T1?M;A]O6IM_/2_F>?,I/ MY@7;75_7WR'[%ZLVEUGB=A[-R>Q>INP\YB=J8[>]!M/&5^\?MZW%S44V3FBS M^1EB>9B-1BM8>^R']WO]TWV.?[MW)O-W,WMGM>[[SNTUWXV44EP]J]Q( MEMJ60,$!A16"CAJZC_FO?-R_?%Q!#=O''&%4JC$#505X<_EI_*WNV3<>5IZO,_([?^Y\]6TN66,UHM2[]"38=WWNVL[.U?9+B74AZTW%E-FY[?K;NH]OXC+[JP=;+CLU3[;HQ1U<]7C M*'(P/`E0Q`J"FM!I(/L/^QO]T'SS[F^VO+7N!SA[CV^Q3[K:QW4-I],TTD=O M*H>)IVU*%D="'*`50&C9!Z>W+GZVLKR:UM[0RA&*EJT!(P:?*OGUC[?_`.%& MGRFZ!V%@NT.ZOY4G='6/7VYY:&#`;PWEGZO#8+)SY.D%=CXJ>MJ<(JB2LI"' MC5M)8?3GW;DG^[#]H?4N0_OA[#NW,MHKF:VMH5EE01MH<[^TB6>ZV"6.%N!8T!KP\NC.?'7_A1+TA\AOA5\J_D[CNK,WM'?WQ.V MAC-U;PZFSF>HI(-R4V>RT&%P$VW-S4\*QO!DLI4+3E)(Q-'*1<$'W$WN;_=F M\_\`MI[\>T'M-=O;VVXQ0L#`T,;2S">`FH*1J7J&TE:Y!'2VSY MRM;S:[^^6`K-;J"4)XU-!0_,]$7Z8_X5B1=N;MJ-FX;X']G;KW%5;=S-;MO; M/66>EWONC.9ZBACEHJ!<1C\*]1#C&!=ZFJTD0(ER+D>\@^>_[G)^2MFCWV^^ M\/M%GMB7423SW\(M((HG)#/XCRA3)P"1UJY/RZ*K7W!%Q(8EVF1GTF@4ZB3] ME.'J>K,/Y?W\W?Y'?,CY&4/1_8?\NWNKXZ;?DVCFMTY/L??5+N"BP^,_AQCB MQ](RYG;N)BG?*U3-&FB0L"AXM[Q4^\A]R[VO]D/;"?G_`)9^\UL/,^Y"]BMT MLK1H6E?74NWZ4TA`C6C&HIGCT>;/S%>[E>BUFV:6%-))9JT'[0./7__1&C_A M8%\CM4_Q:^*>,JQ^S!N'NW=M*I!#?=22;1V@'L;J\0H\FUB/TR`CZ^^_/]RA M[7T7W=]X;N$Y:':[=O32!OS<_X!_EZ)O_PGA_D[ M_&OY_P#7'??<'RKP>YLWM3;6Y]M[%ZYI,'NBKVHDF8%#69;==;+4T>J6M>EA MDHXE0C2HE)^ON+JTGN[UI;=;@B,LL=N@5 ML*&(E8GB=('#HLY.Y;L=W@N[G<%8QJP5:&F>)_R=4@?S,^L^A.BOGA\@^J/B MXF3ING^L]ZTVVMJ-E,X=R5:9'#8;%KN(KEI$U5<,.YQ5(@;45":23;WG[]U' MFOW%]PON[^VO./NXT3\[[M8-/<>'%X"E)99/!_3&%)@\,FE*UKT%]\@M+3=K MRWL*_31M05-<@"N?MKU>A_-/_FN_-'IKXW?R^/BWL7L?-=+[\?XI]?=L]Y9W MKF"GV7D]Q5N\*;_?B8>),5#!_"<;2;?QHJJE(=`JJJ?6W`L>>_W0?N=^Q//7 MNC]Y7W<;S;MIBO2UTD*VQ_P`;E)D)\1VF?PXRU?#C32/4"K?> M8-SM;+9["&`KN5[2:_",Y"\L[-KC3%#_C%T4!18A`Y(BU@$EA4@\!TLVS;- M[O=H_>TW,,L::6:F3A:^=1QIUJS_`!:ZKSGRV^:W2W4^2RU=NG,]X][[:P6= MSV4J9I)J MOJR_/C"?$JA^$?;?7GRWW3MCK[XYY+KI]FYK)YJHIH9,734M)!2X"7:M+*&J M:_<^+K::GFH(J9'G\T2D"P)'Q\?=TO\`WEF]^^3.9?9C:+O#F38+2'F+:K5YI8HS/;N$N(HYPJL\9U`J_A28!('P@T'6.Q8P MRL8G8`$T.02/7\QU]2_^4?D/A%UU_+,V?WO\1]AXK9>P(^M,YN_LIZAZ>OWU M5[TV/BJVIWG1;\W)8U^4RM)D:&3Q!V$:021E$4-[^13[Y]M[^JWSV[]Y M^8IK_F4[K%;6(`*6BVMU(JVK6D'P1QLCKJH*E@P9C3J>.7&VN'8X[O;H0L.@ MEO-M2CNU'S/7S>-GT^=^=?\`,+VY!E*R2LRGR5^3V.^^JZF,S.F-WIOV-YS) M$S`NE!@I2H4V],8!]_47O4FW_=Z^[/N;VD(CM.5>4GT*IH#):V9`H?+7,*U] M3U"T0?=MYC#&K3S_`,F;_-U]9_O3>^&^-/Q9[1WYK%'A^E>D]SY>C^W@$:1K ML[9U3_"XXJ>,>--=321*JC@7_P`/?QL>WVP7WNG[NDJ:G2?9 M/V?YGYLYJDGM>2=FVW1)],*S)"%6!%@%1^IW*J9%#3K':QMKGEP=0:JBHZ>=C'$0`K\_CWQ`]@OO1?W:/W;><=SYZ]M=EYX' M,=W:M`\EW']2`CN'?0&E&EF(%6KPQU(^Z;+SCO%NEM>26W@JU0%-,_LZJ@^5 M7P8[D_D^_P`LON[J[O[*[!F[@^;O='6>U,+1[&SLFX$HNJNHP^^,S/45LE!0 M2(V5W$*>-H]!540XKR3R#L-]<2M=PB$ON M&XTM(@JAW%(X=9!K4D\*#H@O]KN>7=DNK>[*_4W4J@:37L3N/[3T;3_A(;\? MDW+\@/D9\D\C1PR0]:[$Q?7NVJYX]4U/G=[U,E7FEAK"T$88CDAK?0^X M;_OI_V'M9:SL'W3<)+V=*X:*U4+$3Z_JNU/F*]&'MU9Z[R]O6&$0* M#\VX_P`NM_;\ZK>K3IU6]6F]]-_K:_OYR.I=Z__2MS_F2_\`"=[O%-+//NR;9=W8 M72'FN$E?2,A=3VY-`>`K3HM3V^EC!6/>G5?0*1_S]URZ_P#^$A'7^+[$VQN7 ML[Y<;DWYM*BW'19C=FVZ38T&*R>ZZ&GK(ZVMQ4F=GS5;-2?Q<(T&*6.6TD4A\@8@'WB[ M]T;^\CY]^[)LW-?+&Z\KP\P\O[E?R7RJ\OT\L-W.Q:X<.J,&6=B&92O:R]I` M)'1SO_*%MO,D$TQO^$WW>&V>JLKT%D_YGW>%1T/6;6S MV#INJL%AGPVU%JLE&9*$5E`K:W+9*CVGD.NXL5'/D M^)X9)IIIFE/7HV_;O\E3._ M,GY28GO+^8!\H<[\B.I-F5>2J>O_`(QX#;'^CKK'!13U)?'4&0.)RKY#+PP0 M!?NIG<55:RVDD\9*^X7Y+^_=M_L=[1WOM_\`=O\`:6VY9YSOT1;S?II_K;^4 MA:.Z>)&$C)-?#4#PX@:JNH`]&5QRRVY7XN=WOC-;K73$!I4>E:&I^?F>@X_F M@_\`"=_IK^8%V1UGV1U_O[&?&ROV-U]3]QR3W;) M)!+**7'<4>">&80%$TD!:@@&'-[? MJI*:IA30&;3("'4'V!/O=_?:VS[SV^<@\[[9[8+R[[B[#.K1WT=SXQDB1A)% M&Z&-03%,H='-2!5>!Z5;!RX^RQW-N][XMI*,J5I0\"0:^8P>JLZO_A)EA-H= MSR]J]!?-/>/4Z8#>B;PZRB78]+E-Q;$GHZY^15Y/]Q_8FQWDW-@;:^/U31PW89-$A,/AMI$JY90U`2=- M!2A"?;Y8[KZFSW)HP&U+VU*^8S7RZN,Z0_EP?**GF[&VW\T/Y@G9/S`Z;[%Z MHW;UCDNJ,UM#";)Q!.[X(*&KW%45^"9:VJR>.H(W6ENP$4DI?D@>\(.?_O0> MTDJ,FY[P]S;O&5*$!1GSJ/,>75.FT/^$HF0Z9[K]P[3SM1F>OL M_3;"Q\V[-L:O-'2_[EJ;+4U-4U<5),8G?PJLBDW7D^\WMZ_OA[?GGDNYY,]R M_NY[=N^V7ELL5Y"UVXMY^!;]-HV(4L-0&HE32AQT&T]OS;7(N+/=WC=353IR M/SKT>\_RG?YI-C;^>#\@[VXOL?"D7_%Q]X/S[QW_`.#$^Z-_[('RU_V5R_\` M0/1O_5_??^FIF_WD=)#YX?R#.S/GGM7XU[8[0^0%.K8?>'70@Z__3 MW\/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>] ;^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=?__9 ` end